VINORELBINE CAPECITABINE EPIRUBICINE AS FIRST LINE THERAPY IN ADVANCED BREAST CANCER PATIENTS - VNBCAP EPI

Status

Not yet recruiting

Phases

Unknown

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2005-005681-36-IT

Enrollment

Registered

2006-02-06

Start date

2006-02-22

Completion date

Unknown

Last updated

2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

METASTATIC BREAST CANCER MedDRA version: 6.1 Level: PT Classification code 10055113

Interventions

Trade Name: NAVELBINE 10MG/ML FL1ML Pharmaceutical Form: Solution for infusion INN or Proposed INN: Vinorelbine Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10-

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: METASTATIC BREAS CANCER ONE LESION MEASURABLE FOR RECIST CRITERIA ADJUVANT CHEMOTHERAPY ENDED MORE THAN 12 MONTHS BEFORE PROGRESSION Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: PREVIOUS CHEMOTHERAPY FOR ADVANCED DISEASE PREVIOUS THERAPY WITH VINORELBINE PREVIOUS SECOND AND THIRD LINE HORMONOTHERAPY FOR ADVANCED DISEASE

Design outcomes

Primary

Measure	Time frame
Main Objective: ACTIVITY;Secondary Objective: TOXICITY TIME TO PROGRESSION OVERALL SURVIVAL;Primary end point(s): RESPONSE RATE EVALUATED WITH RECIST CRITERIA	—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026